SGX Pharmaceuticals (formerly Structural GenomiX) is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics.

SGX's oncology pipeline includes drug candidates from its enabling, proprietary FAST™ drug discovery platform, such as next generation BCR-ABL inhibitors currently being developed in partnership with Novartis, MET tyrosine kinase inhibitors including SGX523, and lead series of potent JAK2 inhibitors.